/L without transfusion for at least 7 days. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03, Washington, DC, USA), and hepatic veno-occlusive disease (VOD) was diagnosed according to the Baltimore criteria. The analysis was performed with Statistical Package for the Social Sciences (SPSS) software version 19 (SPSS Inc., New York, NY, USA). P-values o 0.05 were considered to be statistically significant. Kaplan-Meier analysis was used to evaluate overall survival (OS) and event-free survival (EFS), and the log-rank test was used for subgroup comparisons.
Nineteen patients (13 male, 6 female) who were diagnosed with osteosarcoma at a median age of 11.8 years (range, 5.4-15.7 years) underwent HDCT and ASCT at a median age of 12 years (range, 6-20 years). Indications for HDCT and ASCT were tumor necrosis o90% (n = 8), initial metastasis (n = 2), relapse (n = 3), a combination of tumor necrosis o 90% and initial metastasis (n = 3), a combination of tumor necrosis o90% and progression (n = 2), and a combination of tumor necrosis o90%, initial metastasis and progression (n = 1) ( Table 1) . A median of 6.1 × 10 6 /kg (range, 1.6-15.7 × 10 6 /kg) CD34 + cells were infused for ASCT. One patient died before engraftment. In the other 18 patients, neutrophils engrafted at median 10 days (range, 8-11 days), and platelets engrafted at median 18 days (range, 14-26 days) after infusion of the autologous PBSCs.
There were three cases (16%) of severe non-hematologic toxicities, but all of them were transient. One patient had a grade IV increase in creatinine, and another patient had a grade IV increase in alanine aminotransferase and aspartate aminotransferase; both of them recovered with supportive care. One patient had a grade IV acute kidney injury and underwent continuous renal replacement therapy, but recovered and is currently on regular follow-up at the outpatient clinic. Four patients (21%) had VOD, but all of them had moderate-grade VODs that resolved after supportive care.
The OS of the study population was 78.3%, and the EFS was 67.4% at a median follow-up of 31 months (range, 1-91 months) from HDCT and ASCT (Figure 1a ). Five patients (26%) relapsed at median 9 months (range, 3-15 months) from HDCT and ASCT. Of these patients, three agreed to undergo further chemotherapy, and all of them are currently alive: two without disease (patient 8 and patient 9) and 1 with disease (patient 16). After relapse, patient 8 completed 13 cycles of chemotherapy with ifosfamide, cyclophosphamide and etoposide, patient 9 completed 8 cycles of chemotherapy with gemcitabine and doxetacel, and patient 16 is currently undergoing chemotherapy with cyclophosphamide, topotecan and etoposide. The two patients who refused further therapy after relapse died of the disease at median 16 months (range, 2-29 months) from relapse. There was one case of transplantation-related mortality (TRM); patient 14 died of unexplained sudden cardiac arrest on day 4.
In a separate analysis of the eight patients with tumor necrosis o90% after neo-adjuvant chemotherapy as the sole factor that designated them as high-risk osteosarcoma, these patients had an OS of 100% and an EFS of 87.5% at a median follow-up of 27 months (range, 9-61 months) from HDCT and ASCT (Figure 1b) . In a comparison analysis, patients with initial lung metastasis (all patients with initial metastasis had metastases limited to the lungs) had significantly worse EFS compared with those without (33.3% versus 83.9%) (P = 0.026) (Figure 1c ). Four patients had bilateral lung metastases; three of these patients relapsed after HDCT and ASCT and one patient died of TRM. None of the patients with unilateral lung metastasis relapsed. In another comparison analysis, patients with two or more factors that designated them Letter to the Editor as high-risk osteosarcoma had significantly worse EFS compared with those with only one factor (33.3% versus 83.9%) (P = 0.019) (Figure 1d) .
The possible role of HDCT and ASCT in osteosarcoma has been suggested in studies that showed that dose escalation and intensification are effective in osteosarcoma. 9, 10 Although methotrexate, doxorubicin, cisplatin and ifosfamide were shown to be active agents in osteosarcoma, their uses in high doses are limited owing to their toxicities. 11 However, high doses of etoposide and carboplatin have been shown to have antitumor effect with suitable toxicity profiles. 9, 12 Previous studies on HDCT and ASCT in osteosarcoma used heterogeneous conditioning regimens and showed varying outcomes. 3, 13, 14 The current analysis of high-risk osteosarcoma patients treated with HDCT and ASCT with a uniform conditioning regimen MEC at our institute showed promising results. This regimen was also promising for patients with tumor necrosis o 90% after neo-adjuvant chemotherapy as the sole factor that designated them as high-risk osteosarcoma.
However, a quarter of the current study population relapsed after a single course of HDCT and ASCT with MEC, which suggests that a single course may not be sufficient for a certain group of high-risk osteosarcoma patients. As the patients with initial lung metastasis or those with two or more factors had significantly worse EFS, further treatment strategies may be needed to overcome relapses after a single course of HDCT and ASCT with MEC in these patients (Figure 1c and d) . Because all three patients who underwent additional chemotherapy after relapse are currently alive, additional chemotherapy after a single course of HDCT and ASCT or even tandem HDCT and ASCT may be the possible treatment options. Also, the presence of a TRM necessitates further refinements in current practice.
The current study results should be interpreted with caution. First, this study is a retrospective review of a small number of patients who were treated in a single institute and were followed up for a short period of time. Second, owing to the small size of the study population, the effects of HDCT and ASCT could not be analyzed separately for each of the indications for HDCT and ASCT. Third, a substantial portion of the study population had tumor necrosis o 90% after neo-adjuvant chemotherapy as the sole factor that designated them as high-risk osteosarcoma. To overcome these limitations, prospective multicenter collaboration studies on a greater number of patients are needed to further The EFS of the patients with initial lung metastasis (broken line) was significantly lower than that of those without initial lung metastasis (solid line). (d) High-risk osteosarcoma was defined as the presence of one or more of the following factors: tumor necrosis o90% after neo-adjuvant chemotherapy, metastasis, progression on therapy or relapse. The EFS of the patients with two or more factors (broken line) was significantly lower than that of those with one factor (solid line).
verify the efficacy of this treatment regimen. Nonetheless, the current study managed to suggest that HDCT and ASCT with MEC may be a promising treatment option for high-risk osteosarcoma.
